Medibank Private Ltd (ASX: MPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Medibank Private Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $10.13 billion
P/E Ratio 16.24
Dividend Yield 4.22%
Shares Outstanding 2.75 billion
Earnings per share 0.226
Dividend per share 0.14
Year To Date Return 5.11%
Earnings Yield 6.16%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Medibank Private Ltd (ASX: MPL)
    Latest News

    Stethoscope with a piggy bank and hundred dollar notes.
    Dividend Investing

    Medibank shares: Here's the dividend yield you'll get today

    Medibank stock offers a decent dividend yield today.

    Read more »

    Two businessmen look out at the city from the top of a tall building.
    Broker Notes

    Buy or hold? Top broker rates these 2 ASX 200 shares

    One player stands out more than the other.

    Read more »

    A man looking at his laptop and thinking.
    Financial Shares

    Medibank shares dip as huge potential fines loom from 2022 data breach

    The regulator has stepped in on the case.

    Read more »

    Woman on her laptop thinking to herself.
    Healthcare Shares

    What is Goldman Sachs saying about Medibank shares in June?

    Let's see if the broker thinks that investors should be buying this private health insurer.

    Read more »

    a smiling woman holds up two fingers and winks.
    Dividend Investing

    Overinvested in CBA shares? Here are two alternative ASX dividend stocks

    It could be smart to diversify with these passive income ideas.

    Read more »

    Woman with headphones on relaxing and looking at her phone happily.
    Dividend Investing

    Here's how I'd target a $2,000 second income by investing $35 a week

    This would be my strategy to make investment income.

    Read more »

    a man with a wide, eager smile on his face holds up three fingers.
    Opinions

    Here are 3 reliable ASX shares I'd buy instead of the big four banks right now

    I’m banking on these stocks to pay more reliable dividends than the financial sector.

    Read more »

    Person holding Australian dollar notes, symbolising dividends.
    Opinions

    With $1,000 to invest, should I buy ASX growth stocks or income shares?

    Here’s my view on which investment Aussies should look at.

    Read more »

    an older man dressed in singlet wearing thick neck chains and a side turned cap holds up two fingers while operating DJ mixing equipment with a record player and headphones around his neck.
    Superannuation

    Why I'd buy high-yield ASX dividend shares for superannuation in retirement

    High-yield ASX dividend shares can make a lot of sense in retirement.

    Read more »

    An older man throws his hands up in excitement as he rides a carnival swing high up in the air.
    Superannuation

    Top ASX shares to buy for your superannuation fund in May 2024

    Is your super working hard for you?

    Read more »

    Shot of a mature scientists working on a laptop in a lab.
    Healthcare Shares

    Down 10% since mid-March, are Medibank shares a buy or a sell?

    Is this stock a healthy opportunity?

    Read more »

    An older couple hold hands as they bounce happily high in the air.
    Opinions

    3 ASX stocks to benefit from Australia's ageing population

    Ageing demographies is a strong tailwind.

    Read more »

    Frequently Asked Questions

    Medibank Private was established by the Australian government in 1976 as a not-for-profit private health insurer. It converted into a for-profit entity in 2009 before listing on the ASX in November 2014.

    Yes, Medibank Private has paid dividends to shareholders every year since 2015. Typically, it pays an interim dividend in March and a final dividend in September, both fully franked.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    29 Feb 2024 $0.0720 100.00% Interim 20 Mar 2024
    13 Sep 2023 $0.0830 100.00% Final 05 Oct 2023
    02 Mar 2023 $0.0630 100.00% Interim 22 Mar 2023
    07 Sep 2022 $0.0730 100.00% Final 29 Sep 2022
    04 Mar 2022 $0.0610 100.00% Interim 24 Mar 2022
    08 Sep 2021 $0.0690 100.00% Final 30 Sep 2021
    03 Mar 2021 $0.0580 100.00% Interim 25 Mar 2021
    02 Sep 2020 $0.0630 100.00% Final 24 Sep 2020
    03 Mar 2020 $0.0570 100.00% Interim 26 Mar 2020
    04 Sep 2019 $0.0740 100.00% Final 26 Sep 2019
    05 Mar 2019 $0.0570 100.00% Interim 28 Mar 2019
    05 Sep 2018 $0.0720 100.00% Final 27 Sep 2018
    06 Mar 2018 $0.0550 100.00% Interim 28 Mar 2018
    06 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    07 Mar 2017 $0.0525 100.00% Interim 29 Mar 2017
    06 Sep 2016 $0.0600 100.00% Final 28 Sep 2016
    04 Mar 2016 $0.0500 100.00% Interim 29 Mar 2016

    MPL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Medibank Private Ltd

    Previously owned by the Australian government, Medibank Private Ltd (ASX: MPL) is the largest health insurer in Australia.

    As of November 2022, its two brands, Medibank Private and ahm, provide cover to almost five million people.

    Medibank and Australia's fourth-largest health fund, NIB Holdings Limited (ASX: NIB), are the only health insurers listed on the ASX.

    In addition to private health insurance, the company provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.

    MPL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Jun 2024 $3.67 $-0.03 -0.81% 12,097,498 $3.69 $3.71 $3.64
    19 Jun 2024 $3.70 $-0.04 -1.07% 10,625,469 $3.74 $3.77 $3.70
    18 Jun 2024 $3.74 $-0.03 -0.80% 8,399,289 $3.80 $3.80 $3.74
    17 Jun 2024 $3.77 $0.08 2.17% 5,037,085 $3.69 $3.79 $3.68
    14 Jun 2024 $3.69 $-0.03 -0.81% 3,832,910 $3.72 $3.73 $3.67
    13 Jun 2024 $3.72 $0.01 0.27% 9,065,797 $3.71 $3.74 $3.61
    12 Jun 2024 $3.71 $-0.01 -0.27% 3,662,933 $3.72 $3.75 $3.70
    11 Jun 2024 $3.72 $-0.07 -1.85% 6,282,239 $3.76 $3.77 $3.71
    07 Jun 2024 $3.79 $0.01 0.26% 3,685,687 $3.75 $3.81 $3.75
    06 Jun 2024 $3.78 $0.06 1.61% 9,413,647 $3.73 $3.79 $3.72
    05 Jun 2024 $3.72 $-0.03 -0.80% 7,830,256 $3.75 $3.76 $3.69
    04 Jun 2024 $3.75 $-0.02 -0.53% 4,261,418 $3.77 $3.79 $3.74
    03 Jun 2024 $3.77 $0.05 1.34% 3,697,675 $3.74 $3.77 $3.73
    31 May 2024 $3.72 $0.07 1.92% 17,108,086 $3.68 $3.74 $3.68
    30 May 2024 $3.65 $0.01 0.27% 3,535,867 $3.61 $3.66 $3.61
    29 May 2024 $3.64 $0.00 0.00% 6,803,242 $3.61 $3.66 $3.61
    28 May 2024 $3.64 $-0.01 -0.27% 4,859,523 $3.67 $3.68 $3.64
    27 May 2024 $3.65 $0.03 0.83% 4,104,688 $3.62 $3.66 $3.60
    24 May 2024 $3.62 $-0.04 -1.09% 4,210,872 $3.62 $3.64 $3.60
    23 May 2024 $3.66 $0.01 0.27% 3,668,089 $3.65 $3.68 $3.62
    22 May 2024 $3.65 $0.01 0.27% 7,324,203 $3.68 $3.70 $3.64

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Feb 2024 Linda Nicholls Buy 5,400 $19,710
    On-market trade.
    11 Dec 2023 David Koczkar Issued 653,088 $2,292,338
    Issue of securities. 2,100,777 Performance Rights
    24 Oct 2023 David Koczkar Transfer 568,030 $1,993,785
    As advised by the company. Transfer of 568,030 Ordinary Shares
    24 Oct 2023 David Koczkar Transfer 568,030 $1,993,785
    As advised by the company. Transfer of 568,030 Ordinary Shares
    26 Sep 2023 David Koczkar Exercise 240,566 $832,358
    Conversion of securities. 1,447,689 Performance Rights
    26 Sep 2023 David Koczkar Issued 14,875 $51,467
    As advised by the company. Ordinary Shares having an equivalent value to the dividends that would have been received during the deferral period if Ordinary Shares were held instead of the Performance Rights granted under the FY22 Deferred STI.
    26 Sep 2023 David Koczkar Buy 240,566 $832,358
    Conversion of securities.
    01 Sep 2023 David Koczkar Buy 128,726 $467,275
    Conversion of securities.
    01 Sep 2023 David Koczkar Expiry 77,896 $282,762
    As advised by the company. lapsing of Performance Rights, 16,88,255 Rights
    01 Sep 2023 David Koczkar Exercise 128,726 $467,275
    Conversion of securities. 17,66,151 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael (Mike) John Wilkins Non-Executive DirectorNon-Executive Chairman May 2017
    Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He served as Managing Director and Chief Executive Officer at Insurance Australia Group (November 2007 to November 2015), Managing Director and Chief Executive Officer at Promina Group Limited and Managing Director at Tyndall Australia Limited. He also served as Acting Chief Executive Officer (April 2018 to December 2018), Executive Chairman (April 2018 to June 2018) and a director (September 2016 to February 2020) of AMP Limited. He was previously a director of Maple-Brown Abbott Limited, Alinta Limited, The Geneva Association and the Australian Business and Community Network. He is also a director (since November 2016) of QBE Insurance Group Limited. He is also a director of Scentre Group Limited (since April 2020). He is a member of the Investment and Capital Committee and the People Committee.
    Mrs Linda Bardo Nicholls Non-Executive Director Mar 2014
    Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is currently a director of Inghams Group Limited (since November 2016). Linda is also Chair of the Board of Melbourne Health and a member of the Museums Victoria Board. Linda's previous directorships include Japara Healthcare Limited as Chair (March 2014 to November 2021), Fairfax Media Limited and Sigma Pharmaceuticals Limited. She is Chair of the Investment and Capital Committee and a member of the Risk Management Committee.
    Ms Kathryn Joy Fagg Non-Executive Director Mar 2022
    Ms Fagg is currently a director of National Australia Bank Ltd (since December 2019), Djerriwarrh Investments Ltd (since May 2014) and she is the Chair of CSIRO. In the non-forprofit sector, she is Chair of Watertrust Australia Ltd and Breast Cancer Network Australia, a director of The Myer Foundation, the Grattan Institute and the Champions of Change Coalition. Kathryn was a non-executive director of Boral Limited from September 2014 to July 2021 including as Chair from July 2018, a non-executive director of Incitec Pivot Limited from April 2014 to December 2019, and a member of the board of the Reserve Bank of Australia from 2013 to 2018. She is a member of the Audit Committee and the People Committee.
    Mr David Fagan Non-Executive Director Mar 2014
    Mr Fagan held a range of leadership positions at Clayton Utz culminating in the role of Chief Executive Partner for nine years. In this role, David had responsibility and accountability for leadership and transformation, strategy, finance, stakeholder engagement, and governance, including risk management. During David's tenure as Chief Executive Partner, Clayton Utz entrenched itself as a first class top tier commercial law firm. David also chaired the Medibank Privatisation Committee which operated during 2014 in preparation for the privatisation process. David is a former director and Chair of the Audit Committee of The Global Foundation, a former director of Grocon Funds Management Group, the Hilco Group and UBS Grocon Real Estate Investment Management Australia Pty Limited and a former member of the advisory board of Chase Corporate Advisory. David is currently a director of PayGroup Limited (since November 2017). He is Chair of BDO Group Holdings Limited and a member of the ASIC Corporate Governance Consultative Panel. He is Chair of the Risk Management Committee.
    Mr David Koczkar Chief Executive OfficerManaging Director May 2021
    Mr Koczkar has more than 25 years of strategy, customer and commercial experience, including previous work in the strategy consulting and financial services industries. Prior to joining Medibank, David was the Group Chief Commercial Officer at Jetstar where he was responsible for the airline group's network management, sales and marketing, customer channels and commercial operations, including as a director of Jetstar Pacific (Vietnam), Jetstar Hong Kong and NewStar (Singapore) JV businesses.
    Mr Peter Dobie Everingham Non-Executive Director Mar 2022
    Mr Everingham has over 25 years of corporate experience and is highly respected in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes key roles at companies with a consumer and technology focus. Peter is currently a director of Super Retail Group Limited (since December 2017), the owner of several notable Australian brands including BCF, Macpac, Rebel and Supercheap Auto. He is also a director of WWF Australia. He was previously a director of iCar Asia Limited (July 2017 to May 2022), Managing Director of the international division of Seek Limited (and concurrently Chair of Seek's subsidiary, Zhaopin), a director of ME Bank and IDP Education Ltd, and a senior executive for Yahoo! in Australia and Southeast Asia. He is a member of the the People Committee.
    Dr Tracey Leigh Batten Non-Executive Director Aug 2017
    Dr Batten has experience in the health services sector, with commercial, business and change leadership skills. Tracey is currently a director of EBOS Group Limited (since July 2021), the National Institute of Water and Atmospheric Research in New Zealand and the New Zealand Accident Compensation Corporation, and a former director of Abano Healthcare Group. Tracey was previously the Chief Executive of the Imperial College Healthcare NHS Trust in the United Kingdom. In that role, Tracey focused on change leadership, in particular improving organisational culture and strengthening patient safety and experience. Tracey also oversaw the implementation of a range of digital initiatives as Chief Executive. Tracey is a former Chief Executive of St Vincent's Health Australia, which runs a group of public hospitals, private hospitals and aged care facilities. She is Chair of the People Committee and a member of the Risk Management Committee.
    Mr Gerard Dalbosco Non-Executive Director May 2021
    Mr Dalbosco held a number of senior leadership roles as a Partner of EY until September 2020. His recent role was Melbourne Managing Partner where he led a team responsible for EY's go-to-market and client service strategies. Prior to this, Gerard held other roles at EY including Asia Pacific Managing Partner - Markets and Co-Deputy CEO where he led EY's client-serving activities across the Asia Pacific market. He was also Oceania Managing Partner and CEO, and Oceania Managing Partner of Transaction Advisory Services where he was responsible for EY's Transaction Advisory Services business across Oceania. Gerard is currently Chair of Melbourne Archdiocese Catholic Schools. He has previously held roles as a director and Chair of the Finance & Audit Committee of Mercy Health & Aged Care, director and member of the Finance Committee of Berry Street Victoria and director and Co-Deputy Chair of the Committee for Melbourne. He is a member of the Risk Management Committee.
    Mr Jay Wilson Weatherill Non-Executive Director Mar 2024
    --
    Ms Mei Ramsay Group General CounselCompany Secretary Mar 2011
    -
    Mei Ramsay Group General CounselCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Hsbc Custody Nominees (Australia) Limited 886,438,939 32.19%
    J P Morgan Nominees Australia Pty Limited 454,621,638 16.51%
    Citicorp Nominees Pty Limited 352,442,059 12.80%
    National Nominees Limited 135,979,370 4.94%
    Bnp Paribas Noms Pty Ltd <Drp> 72,474,536 2.63%
    Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 27,460,612 1.00%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 26,018,991 0.94%
    Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 26,018,991 0.68%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 6,934,877 0.25%
    HSBC Custody Nominees (Australia) Limited (ii) 6,394,969 0.23%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 6,036,480 0.22%
    Bond Street Custodians Limited <Cockej F01832 A/C> 4,808,007 0.17%
    Netwealth Investments Limited <Wrap Services A/C> 4,671,507 0.17%
    BNP Paribas Noms (Nz) Ltd <Drp> 4,407,028 0.16%
    Ioof Investment Services Limited <Ips Superfund A/C> 4,291,839 0.16%
    Navigator Australia Ltd <Sma Antares Inv Dv Build A/C> 3,721,738 0.14%
    Netwealth Investments Limited <Super Services A/C> 3,067,565 0.11%
    Solium Nominees (Australia) Pty Ltd <Vsa A/C> 2,522,537 0.09%
    Hsbc Custody Nominees (Australia) Limited A/C 2 2,485,524 0.09%
    BNP Paribas Nominees Pty Ltd <Agency Lending Collateral> 2,279,500 0.08%

    Profile

    since

    Note